Table 2.
Baseline characteristics of patients with and without pod and patients who died by Day 28
| Without POD at Day 28 (n = 324) | With POD at Day 28 (n = 113) | Dead by Day 28 (n = 163) | P-value*a | |
|---|---|---|---|---|
| Age | <0.001bc | |||
| 62.6 ± 14.4 | 61.8 ± 13.8 | 67.9 ± 13.5 | ||
| Sex | 0.63 | |||
| Male | 198 (61.1%) | 70 (61.9%) | 93 (57.1%) | |
| Female | 126 (38.9%) | 43 (38.1%) | 70 (42.9%) | |
| Admission type | <0.001ab | |||
| Medical | 233 (71.9%) | 100 (88.5%) | 137 (84.0%) | |
| Surgical: Elective | 42 (13.0%) | 6 (5.3%) | 8 (4.9%) | |
| Surgical: Emergency | 49 (15.1%) | 7 (6.2%) | 18 (11.0%) | |
| Primary ICU diagnosis | 0.004a | |||
| Cardiovascular/vascular | 29 (9.0%) | 10 (8.8%) | 19 (11.7%) | |
| Respiratory | 101 (31.2%) | 32 (28.3%) | 49 (30.1%) | |
| Gastrointestinal | 5 (1.5%) | 2 (1.8%) | 6 (3.7%) | |
| Neurologic | 3 (0.9%) | 1 (0.9%) | 1 (0.6%) | |
| Sepsis | 83 (25.6%) | 43 (38.1%) | 54 (33.1%) | |
| Trauma | 2 (0.6%) | 2 (1.8%) | 1 (0.6%) | |
| Metabolic | 7 (2.2%) | 1 (0.9%) | 4 (2.5%) | |
| Hematologic | 1 (0.3%) | 2 (1.8%) | 0 (0.0%) | |
| Other | 2 (0.6%) | 7 (6.2%) | 3 (1.8%) | |
| Post-op: Vascular/cardiovascular | 51 (15.7%) | 9 (8.0%) | 10 (6.1%) | |
| Post-op: Respiratory | 4 (1.2%) | 0 (0.0%) | 2 (1.2%) | |
| Post-op: Gastrointestinal | 21 (6.5%) | 2 (1.8%) | 10 (6.1%) | |
| Post-op: Trauma | 4 (1.2%) | 2 (1.8%) | 1 (0.6%) | |
| Post-op: Renal | 2 (0.6%) | 0 (0.0%) | 0 (0.0%) | |
| Post-op: Orthopedic | 1 (0.3%) | 0 (0.0%) | 2 (1.2%) | |
| Post-op:Other | 8 (2.5%) | 0 (0.0%) | 1 (0.6%) | |
| Charleson Comorbidity Index | <0.001 ab | |||
| 1.2 ± 1.5 | 1.7 ± 2.0 | 1.7 ± 1.7 | ||
| Functional Comorbidity Index | 0.62 | |||
| 1.3 ± 1.4 | 1.2 ± 1.4 | 1.4 ± 1.4 | ||
| APACHE II | <0.001ab | |||
| 24.4 ± 6.6 | 28.4 ± 5.9 | 29.1 ± 8.0 | ||
| Day 1 SOFA score | <0.001abc | |||
| 7.8 ± 2.6 | 9.4 ± 2.8 | 8.7 ± 2.9 | ||
| Etiology of shock | 0.16 | |||
| Cardiogenic | 76 (23.5%) | 20 (17.7%) | 32 (19.6%) | |
| Septic | 203 (62.7%) | 81 (71.7%) | 112 (68.7%) | |
| Neurogenic | 3 (0.9%) | 1 (0.9%) | 0 (0.0%) | |
| Not in shock | 7 (2.2%) | 4 (3.5%) | 2 (1.2%) | |
| Other | 10 (3.1%) | 2 (1.8%) | 7 (4.3%) | |
| Hemorrhagic | 15 (4.6%) | 2 (1.8%) | 1 (0.6%) | |
| Uncertain Origin | 9 (2.8%) | 3 (2.7%) | 9 (5.5%) |
* The global P-value tested against the null hypothesis that all three groups have the same mean or proportion is reported. When the global P-value < 0.05, unadjusted pairwise comparisons were made. Significant (P < 0.05) pairwise comparisons are denoted as follows: a-survivors without POD versus survivors with POD, b-survivors without POD versus decedents, c-survivors with POD versus decedents.
APACHE II, Acute Physiology and Chronic Health Evaluation; ICU, Intensive Care Unit; POD, Persistent Organ Dysfunction Score; SOFA, Sequential Organ Failure Assessment.